Cilostazol derivative, preparation method therefor, and use thereof

By modifying the structure of cilostazol, lauroyl cilostazol was prepared, forming a long-acting injectable formulation. This solved the problem of low bioavailability of cilostazol and achieved long-acting release and high patient compliance.

WO2026232745A1PCT designated stage Publication Date: 2026-11-12ANHUI IPCKE PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/124905
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2025-09-28
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing cilostazol drugs are almost insoluble in water, resulting in low bioavailability, frequent oral administration, and poor patient compliance, making it difficult to meet the needs for long-term treatment of cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome.

Method used

By structurally modifying cilostazol, lauroyl cilostazol was prepared, forming a long-acting prodrug. This prodrug was then formulated for intramuscular, subcutaneous, or intravenous injection, providing a long-lasting therapeutic effect through the slow release of cilostazol in the body after injection.

Benefits of technology

It achieves long-acting release of cilostazol, improves bioavailability, reduces dosing frequency, improves patient compliance, maintains treatment levels for a long time, and reduces toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2025124905_12112026_PF_FP_ABST
    Figure CN2025124905_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to the field of pharmaceuticals, and specifically relates to lauroyl cilostazol, a crystal form thereof, a preparation method therefor, a pharmaceutical composition, and a use thereof. The lauroyl cilostazol of the present application is used for treating cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome.
Need to check novelty before this filing date? Find Prior Art

Description

Cilostazol derivatives, their preparation methods and uses Technical Field

[0001] This application relates to the field of medicinal chemistry, specifically to a sterile lauroylsilostazol, its crystal form, its preparation method, its pharmaceutical formulation, and its pharmaceutical uses. Background Technology

[0002] A recent report on treatment evidence published by the Scientific Research Council states that antiplatelet drugs are the first-line remedy for patients in the acute phase of acute myocardial or cerebral infarction. However, a serious problem is that all commercially available antiplatelet drugs are oral, which makes it very difficult, for example, to administer these drugs to patients who have just suffered an acute myocardial or cerebral infarction, especially in the acute phase, and also to expect immediate effects upon oral administration. The reason all commercially available antiplatelet drug formulations are oral is that all the active ingredients contained in these formulations are poorly soluble in water. Cilostazol, a commonly used antiplatelet drug, is no exception; it is almost insoluble in water, with a solubility of only about 3 μg / ml at room temperature.

[0003] Cilostazol is a novel antiplatelet drug with significant inhibitory effects on platelet aggregation and vasodilation, thereby effectively preventing thrombosis and vascular occlusion. Cilostazol has been widely used both domestically and internationally to treat intermittent claudication and other cardiovascular diseases, demonstrating its important clinical value.

[0004] The chemical name of cilostazol is 6-[4-(1-cyclohexyl-1H-tetrazole-5-ylbutoxy]-3,4-dihydro-2(1H-quinolinone), and its structural formula is as follows:

[0005] It is marketed in the United States under the brand name Sold for the treatment of intermittent claudication, under the brand name in Japan and South Korea. Cilostazol is marketed for the treatment of chronic arterial occlusive disease, including diabetic complications of the peripheral vascular system. It is also approved in Europe. The recommended daily dose is 100 mg BID, or 50 mg BID if co-administered with strong inhibitors of CYP3A4 and CYP2C19. Currently, cilostazol is involved in 15 ongoing clinical trials in areas such as cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome.

[0006] Other trials are investigating cilostazol in combination with other therapies. For example, trials are underway investigating cilostazol in combination with aspirin for patients with ischemic stroke (“Overcoming biochemical aspirin resistance by cilostazol combination therapy (ARCC)”), and trials are also being conducted in combination with aspirin for patients with chronic stroke, investigating the effects of aspirin in combination with cilostazol versus aspirin alone on the progression of intracranial arterial stenosis in 200 patients with chronic stroke and stenosis of 50–99%. The following literature documents cilostazol derivatives: KR2012010800, WO2010063724, and WO2024002783.

[0007] Cilostazol is a white to off-white crystalline powder, slightly soluble in methanol and ethanol, but practically insoluble in water, 0.1N HCl, and 0.1N NaOH. Cilostazol is classified as a Class II drug by the Biopharmaceutical Classification System (BCS), indicating that it is a drug with low solubility and high permeability. This means that the rate-limiting step for oral bioavailability of cilostazol is the dissolution of the drug from its dosage form. These characteristics of cilostazol may present multiple challenges for formulation scientists in dosage form development. Furthermore, due to factors such as frequent dosing, long treatment duration, patient compliance, and low bioavailability, oral dosage forms may not be a suitable approach for treating cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome.

[0008] Despite the beneficial activity of cilostazol, new compounds are still needed to treat the aforementioned diseases and conditions.

[0009] Optimizing drug bioavailability has many potential benefits. For patient convenience and improved adherence, reducing dosing frequency is generally considered desirable. By prolonging the drug's release time, the duration of action per dose is expected to be longer. This then leads to an overall improvement in dosing parameters, such as taking the drug once daily instead of four times daily or once weekly, or even less when daily dosing was previously required. Many drugs are currently administered once daily. However, not all of these drugs have pharmacokinetic properties suitable for an exact 24-hour dosing interval.

[0010] Extending the release period of these drugs would also be beneficial.

[0011] To date, no long-acting injectable drug has been approved in any market for the treatment of cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome. Furthermore, there is a need to successfully optimize the determination of key parameters related to drug development for various clinical candidate drugs or molecules, such as selecting the appropriate dose, dosage form, route of administration, dosing regimen, and effects on animals and humans. Therefore, there is an unmet need for an effective drug delivery system for cilostazol.

[0012] The bioavailability of cilostazol can be improved via the injection route; more specifically, long-acting (sustained-release or extended-release) injectable formulations may provide better bioavailability after intramuscular or subcutaneous administration than the oral route. The expected increase in bioavailability of injectable formulations can provide therapeutic plasma concentration levels, with doses administered intramuscularly or subcutaneously once daily, every three days, weekly, every two weeks, every three weeks, monthly, every two months, every three months, or every six months. The total injectable dose can be significantly lower than the daily oral dose required for the same period, thereby reducing toxicity and improving patient compliance. Therefore, given the advantages associated with long-acting formulations, the need to develop long-acting parenteral formulations of cilostazol remains unmet, which would provide higher compliance while maintaining therapeutic levels of the drug in patient systems for extended periods (days, weeks, months, or even years) for the treatment of cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome, or other related conditions described herein.

[0013] Cilostazol and its various uses have been described in US4277479 "Tetraazolylalkoxykasski styrene derivatives and pharmaceutical compositions comprising them"; US6187790 "Use of cilostazol in the treatment of erectile dysfunction"; US6515128 "Preparation of cilostazol"; US6531603, 6573382, 6531603, 6657061 and 6660864 "Polymorphisms of 6-[4-1(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H-quinone) US6525201, 6660773, and 6740758, “Processes for the preparation of 6-hydroxy-3,4-dihydroquinolinone, cilostazol, and N-(4-methoxyphenyl)-3-chloropropionamide”, and US6825214, “Cilostazol, in its basic purity, and methods for its manufacture thereof”. Preparations of cilostazol and its therapeutic uses are disclosed, for example, in WO2009 / 113741; WO2009 / 107864; and US-issued application US2009 / 0297596. All of these documents are incorporated herein by reference.

[0014] One of the fundamental considerations in drug therapy involves the relationship between blood levels and therapeutic activity. For most drugs, maintaining serum levels between the minimum effective concentration and the potential toxic level is of paramount importance. From a pharmacokinetic perspective, the peaks and troughs of drug blood levels ideally fit within the therapeutic window of serum concentration. For some therapeutic agents, this window is so narrow that dosage formulation becomes crucial.

[0015] The currently approved oral solid dosage form of cilostazol has several drawbacks. For example, its bioavailability is very low, thus requiring patients to bear a large daily burden of pills (100 mg tablets twice daily). Furthermore, due to its low bioavailability and significant food effect, it can cause significant fluctuations in patients' blood levels.

[0016] Non-oral administration routes (e.g., parenteral routes) have been explored for use in other classes of drugs. However, to date, there is no extended-release injectable prodrug formulation of cilostazol. Summary of the Invention

[0017] This application modifies the structure of cilostazol to prepare a prodrug with long-acting properties. This type of drug is formulated into a formulation suitable for intramuscular, subcutaneous, or intravenous injection. After intramuscular, subcutaneous, or intravenous injection, it forms a drug reservoir in the body, from which the drug is slowly, continuously, and stably released and converted into cilostazol, thereby exerting a long-acting effect. This application employs the following technical solution:

[0018] The purpose of this application is to overcome the deficiencies in the prior art and provide lauroylcilostazol or its solvate as shown in formula (Ⅰ):

[0019] In some embodiments, lauroylsilostazol of this application is a sterile active pharmaceutical ingredient (API). The purpose of a sterile API is that it can be directly added when supplying injectable dosage forms, and the production process of the injection is simple, such as simple sterile filtration to achieve sterility of the injection.

[0020] Furthermore, the lauroylcilostazol of this application is crystalline, and its X-ray powder diffraction pattern has characteristic peaks at diffraction angles of 2θ: 5.30±0.2, 7.18±0.2, 9.54±0.2, 13.72±0.2, 14.60±0.2, 16.80±0.2, 16.90±0.2, 18.46±0.2, 19.86±0.2, 20.98±0.2, 21.08±0.2, 22.40±0.2, 23.74±0.2, 25.20±0.2, 26.36±0.2, 26.40±0.2, 27.86±0.2°.

[0021] The endothermic temperature of its crystals by differential scanning calorimetry is 55–58 °C.

[0022] Another object of this application is to provide a method for preparing lauroylcilostazol, the method being as follows:

[0023] Lauroyl cilostazol (Formula I) was prepared by reacting chloromethyl laurate with cilostazol in the presence of a solvent and a catalyst.

[0024] In some embodiments, the preparation method is as follows:

[0025] Step 1: Chloromethyl lauryl ester is prepared by reacting dodecyl chloride with paraformaldehyde in the presence of a catalyst;

[0026] Step 2: The product from Step 1 and cilostazol are reacted with a solvent and a catalyst to prepare lauroyl cilostazol (Formula I).

[0027] In some embodiments, the preparation method further includes step 3.

[0028] Step 3: Prepare pharmaceutical-grade raw material of formula (I) from crude product of formula (I) in a crystallization solvent, as shown in the following reaction formula:

[0029] In some embodiments, the catalyst in step 1 is zinc chloride or aluminum trichloride, preferably zinc chloride; the reaction solvent in step 2 is selected from N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, tetrahydrofuran, and dioxane, preferably N,N-dimethylformamide; the catalyst in step 2 is selected from sodium iodide; in step 3, a series of crystallization methods were screened during the preparation of lauroylcilostazol crystals, and the results are as follows:

[0030] Table 1 Crystallization methods

[0031] In some embodiments, the solvent is selected from one or a combination of several of ethyl acetate, n-hexane, anhydrous ethanol, and anhydrous methanol.

[0032] In some embodiments, the solvent is selected from anhydrous methanol.

[0033] In some embodiments, the temperature of the crystallization process is 0–10°C.

[0034] In some embodiments, the lauroylsilostazol provided in this application is sterile, and is obtained by pre-filtration with a 0.45 μm microporous membrane before crystallization, followed by two stages of sterile filtration and vacuum drying at 0.22 μm.

[0035] Another aspect of this application is to provide a pharmaceutical composition containing lauroylsilostazol.

[0036] In some embodiments, the above-described pharmaceutical composition is administered by injection, and the dosage form includes an injection solution or a lyophilized powder.

[0037] In some embodiments, the above-described pharmaceutical composition is an injectable formulation.

[0038] In some embodiments, the injectable formulation is prepared from the active sterile raw material lauroylcilostazol and related pharmaceutical excipients according to pharmaceutically acceptable methods, wherein the excipients include pharmaceutically necessary components such as suspending agents, antioxidants, stabilizers, wetting agents, and preservatives.

[0039] Another aspect of this application is to provide the use of lauroylsilostazol in the preparation of a medicament for the treatment of cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome.

[0040] Another aspect of this application is to provide the use of lauroylsilostazol in the treatment of cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome. Attached Figure Description

[0041] To more clearly illustrate the technical solutions in the specific embodiments of this application or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0042] Figure 1 shows the structure of lauroylcilostazol.

[0043] Figure 2 shows the blood drug concentration-time curve for Example 14.

[0044] Figure 3 shows the lauroylcilostazol DSC prepared in Example 11.

[0045] Figure 4 shows the XRD of lauroylcilostazol prepared in Example 11. Detailed Implementation

[0046] The following examples further illustrate this application; however, these examples should not be construed as limiting the scope of this application. The following examples all relate to the preparation and related experiments of lauroylcilostazol (hereinafter referred to as YPK-008).

[0047] Example 1:

[0048] Step 1: Preparation of YPK-008 side chains

[0049] Reaction equation:

[0050] Table 2 Material Proportions

[0051] Operation process:

[0052] 2.0 g of paraformaldehyde, 0.2 g of zinc chloride, and 10.9 g of lauroyl chloride were added sequentially to a 250 mL three-necked flask. The mixture was stirred and heated to 105–115 °C for 16 hours (the system turned light black, and the material was not completely dissolved). The mixture was then cooled to room temperature (20–25 °C), and 100 mL of ethyl acetate was added. The mixture was stirred and dispersed for 5 min. The mixture was then filtered under reduced pressure. The mother liquor was washed with 50 mL of 10% sodium bicarbonate aqueous solution twice to separate the layers. The organic phase was washed with 50 mL of water and dried with anhydrous sodium sulfate. The dried organic phase was concentrated under reduced pressure at 57 °C to obtain 7.2 g of a gray oily substance. The oily substance was purified by column chromatography (using cyclohexane as the eluent) to obtain 4.5 g of a colorless oily substance, which was the side chain of YPK-008.

[0053] Step 2: Preparation of YPK-008

[0054] Reaction equation:

[0055] Table 3 Material Proportions

[0056] Operation process:

[0057] 2.0 g of cilostazol and 100 mL of dichloromethane were added to a 250 mL three-necked flask and stirred for several minutes. Then, 2.5 g of triethylamine and 0.8 g of Dmap were added, and after stirring for several minutes, 4.0 g of the YPK-008 side chain (chloromethyl laurate) was added. The reaction was carried out at room temperature (20–25 °C). The reaction was monitored by TLC (λ = 254 nm, PE:EA = 1:1) until completion. The temperature was lowered to 0–10 °C, and 20 mL of water was added to quench the reaction. After separation, the organic phase was washed with 50 mL of water and dried with anhydrous sodium sulfate. The solvent was then concentrated under reduced pressure to dryness, yielding 2.1 g of a yellow oil. The oil was purified by column chromatography (washing agents were dichloromethane and PE:EA = 1:1 in sequence) to obtain 1.3 g of a pale yellow oil. The TLC spot was pure, and the sample was sent for NMR analysis. The batch number was CLTZ-LC-250320-01. The NMR data are shown below:

[0058] 1H-NMR (400MHz, CDCl3): δ7.20~6.73(m,3H); 5.92~5.43(m,2H); 4.17~4.15(m,1H); 4.02(t,2H); 2.96~2 .88(m,4H); 2.72~2.67(m,2H); 2.39~2.29(m,2H); 2.10~1.38(m,16H); 1.32~1.25(m,16H); 0.90(t,3H).

[0059] Example 2:

[0060] Step 1: Preparation of YPK-008 side chains

[0061] Table 4 Material Proportions

[0062] Operation process:

[0063] 10 g of paraformaldehyde, 1.0 g of zinc chloride, and 54.5 g of lauroyl chloride were added sequentially to a 500 mL three-necked flask. The mixture was stirred and heated to 90–95 °C for 16 hours (the system turned light black, and the material was not completely dissolved). The mixture was then cooled to room temperature (20–25 °C), and 500 mL of ethyl acetate was added. The mixture was stirred and dispersed for 5 min. The mixture was then filtered under reduced pressure. The mother liquor was washed with 250 mL of 10% sodium bicarbonate aqueous solution twice to separate the layers. The organic phase was washed with 250 mL of water and dried with anhydrous sodium sulfate. The dried organic phase was concentrated under reduced pressure at 57 °C to obtain 34.2 g of a gray oily substance. The product was purified by column chromatography (using cyclohexane as the eluent) to obtain 21.3 g of a colorless oily substance, which was the side chain of YPK-008. The results were analyzed by 1H NMR. The specific results are shown below: 1 H-NMR (400MHz, CDCl3) δ: 5.739 (s, 2H); 2.414 (s, 2H); 1.688 (q, 2H); 1.44~1.23 (m, 16H); 0.917 (t, 3H).

[0064] Step 2: Preparation of YPK-008

[0065] Table 5 Material Proportions

[0066] Operation process:

[0067] Add 9.0 g of cilostazol and 180 mL of N,N-dimethylformamide to a 500 mL three-necked flask, stir for several minutes until the mixture is completely dissolved, cool to 0–5 °C, add 2.5 g of sodium hydride in batches, stir for several minutes, add 15 g of YPK-008 side chain (chloromethyl laurate) and 5.0 g of sodium iodide, stir for several minutes, then transfer to room temperature (maintain reaction at 20–25 °C). Monitor the reaction for completion by TLC (λ = 254 nm, PE:EA = 1:1), then cool to [temperature missing]. After quenching the reaction with water (150 mL) at 0–10 °C, extract twice with ethyl acetate (250 mL * 2). Combine the organic phases and wash twice with water (250 mL * 2). Dry the organic phase with anhydrous sodium sulfate and concentrate the solvent under reduced pressure to dryness to obtain 16 g of yellow oil. Purify the oil by column chromatography (washing agents were dichloromethane and PE:EA = 1:1 in sequence) to obtain 13.5 g of pale yellow oil. The TLC spot was pure and was the same spot as the product obtained in Case 1.

[0068] Example 3:

[0069] Add 18g of cilostazol and 360mL of N,N-dimethylformamide to a 500mL three-necked flask, stir for several minutes until the mixture is completely dissolved, cool to 0-5℃, add 5.0g of sodium hydride in batches, stir for several minutes, add 30g of YPK-008 side chain (chloromethyl laurate) and 10g of sodium iodide, stir for several minutes, then transfer to room temperature (maintain reaction at 20-25℃). Monitor the reaction for completion by TLC (λ=254nm, PE:EA=1:1), then cool to... After quenching the reaction with water (300 mL) at 0–10 °C, extract twice with ethyl acetate (500 mL * 2). Combine the organic phases and wash twice with water (500 mL * 2). Dry the organic phase with anhydrous sodium sulfate and concentrate the solvent under reduced pressure to dryness to obtain 33 g of yellow oil. Purify the oil by column chromatography (washing solvents were dichloromethane and PE:EA = 1:1 in sequence) to obtain 27.4 g of pale yellow oil. The TLC spot was pure and was the same spot as the product in Case 1.

[0070] Example 4:

[0071] Add 18g of cilostazol and 360mL of N,N-dimethylformamide to a 500mL three-necked flask, stir for several minutes until the mixture is completely dissolved, cool to 0-5℃, add 5.0g of sodium hydride in batches, stir for several minutes, add 15g of YPK-008 side chain (chloromethyl laurate) and 5g of sodium iodide, stir for several minutes, then transfer to room temperature (maintain reaction at 20-25℃). Monitor the reaction for completion by TLC (λ=254nm, PE:EA=1:1), then cool to... After quenching the reaction with water (300 mL) at 0–10 °C, extract twice with ethyl acetate (500 mL * 2). Combine the organic phases and wash twice with water (500 mL * 2). Dry the organic phase with anhydrous sodium sulfate and concentrate the solvent under reduced pressure to dryness to obtain 33 g of yellow oil. Purify the oil by column chromatography (washing solvents were dichloromethane and PE:EA = 1:1 in sequence) to obtain 27.4 g of pale yellow oil. The TLC spot was pure and was the same spot as the product in Case 1.

[0072] Example 5:

[0073] Add 18g of cilostazol and 180mL of N,N-dimethylformamide to a 500mL three-necked flask, stir for several minutes, cool to 0-5℃, add 5.0g of sodium hydride in batches, stir for several minutes, add 30g of YPK-008 side chain (chloromethyl laurate) and 10g of sodium iodide, stir for several minutes, then transfer to room temperature (maintain reaction at 20-25℃). Monitor the reaction for completion by TLC (λ=254nm, PE:EA=1:1), then cool to 0-1℃. After quenching the reaction with water (300 mL) at 0 °C, ethyl acetate (500 mL * 2) was added for extraction twice. The organic phases were combined and washed twice with water (500 mL * 2). The organic phases were dried with anhydrous sodium sulfate and the solvent was concentrated under reduced pressure to dryness to obtain 31 g of yellow oil. The oil was purified by column chromatography (washing agents were dichloromethane and PE:EA = 1:1 in sequence) to obtain 26.3 g of pale yellow oil. The TLC spot was pure and was the same spot as the product in Case 1.

[0074] Example 6:

[0075] 20g of cilostazol and 1000mL of dichloromethane were added to a 2L three-necked flask and stirred for several minutes. Then, 20g of triethylamine and 8g of Dmap were added and stirred for several minutes. Finally, 40g of the YPK-008 side chain was added and reacted at room temperature (20-25℃). The reaction was monitored by TLC (λ=254nm, PE:EA=1:1) until the reaction was complete. The temperature was lowered to 0-10℃ and 200mL of water was added to quench the reaction. The mixture was separated into layers. The organic phase was washed with 500mL of water and dried with anhydrous sodium sulfate. The solvent was then concentrated under reduced pressure to dryness to obtain 21.4g of yellow oil. The oil was purified by column chromatography (washing agents were dichloromethane and PE:EA=1:1 in sequence) to obtain 13.2g of pale yellow oil. The TLC spot was pure and was the same spot as the product in Case 1.

[0076] Example 7:

[0077] 20g of cilostazol and 1000mL of dichloromethane were added to a 2L three-necked flask and stirred for several minutes. Then, 20g of triethylamine and 8g of Dmap were added and stirred for several minutes. Finally, 20g of the YPK-008 side chain was added and reacted at room temperature (20-25℃). The reaction was monitored by TLC (λ=254nm, PE:EA=1:1) until the reaction was complete. The temperature was lowered to 0-10℃ and 200mL of water was added to quench the reaction. The mixture was separated into layers. The organic phase was washed with 500mL of water and dried with anhydrous sodium sulfate. The solvent was then concentrated under reduced pressure to dryness to obtain 20.3g of yellow oil. The oil was purified by column chromatography (washing agents were dichloromethane and PE:EA=1:1 in sequence) to obtain 11.3g of pale yellow oil. The TLC spot was pure and was the same spot as the product in Case 1.

[0078] Example 8:

[0079] 20g of cilostazol and 400mL of dichloromethane were added to a 1L three-necked flask and stirred for several minutes. Then, 20g of triethylamine and 8g of Dmap were added and stirred for several minutes. Finally, 40g of the YPK-008 side chain was added and reacted at room temperature (20-25℃). The reaction was monitored by TLC (λ=254nm, PE:EA=1:1) until the reaction was complete. The temperature was lowered to 0-10℃ and 200mL of water was added to quench the reaction. The mixture was separated into layers. The organic phase was washed with 500mL of water and dried with anhydrous sodium sulfate. The solvent was then concentrated under reduced pressure to dryness to obtain 21.3g of yellow oil. The oil was purified by column chromatography (washing agents were dichloromethane and PE:EA=1:1 in sequence) to obtain 13.0g of pale yellow oil. The TLC spot was pure and was the same spot as the product in Case 1.

[0080] Example 9:

[0081] Take 3.5g of the pale yellow oily substance obtained in step 2 of Example 2, add 7mL of ethyl acetate and 35mL of n-hexane, stir and heat until completely dissolved, slowly cool to 20-25℃ without solid precipitation, continue cooling to -5-0℃, and solid gradually precipitates, keep at -5-0℃ for 3 days to crystallize, filter the obtained solid under reduced pressure, dry under vacuum at 45℃ to obtain 1.1g of white solid, sample batch number: YPK-008-250408-01, HPLC detection result: 99.47%.

[0082] Example 10:

[0083] Take 3.5g of the pale yellow oily substance obtained in step 2 of Example 2, add 35mL of anhydrous ethanol, stir and heat until completely dissolved, slowly cool to 20-25℃ without solid precipitation, continue cooling to -5-0℃, solid gradually precipitates, keep at -5-0℃ for 2 hours to crystallize, filter the obtained solid under reduced pressure, dry under vacuum at 40℃ to obtain 2.1g of white solid, HPLC detection result: 99.33%.

[0084] Example 11:

[0085] Take 3.5g of the pale yellow oily substance obtained in step 2 of Example 1, add 35mL of anhydrous methanol, stir and heat until completely dissolved, slowly cool to 20-25℃ without solid precipitation, continue cooling to -5-0℃, solid gradually precipitates, keep at -5-0℃ for 2 hours to crystallize, filter the obtained solid under reduced pressure, dry under vacuum at 40℃ to obtain 1.6g of white solid, HPLC detection result: 99.54%.

[0086] Table 6. Results of 1H NMR Spectroscopy

[0087] Table 7 Mass spectrometry detection results

[0088] Table 8 Infrared Detection Results

[0089] TGA testing results indicate that this product contains no water of crystallization or solvents and begins to decompose at approximately 360°C.

[0090] DSC test results show that this product does not contain water of crystallization or crystallization solvent, and its melting point is 57.39℃.

[0091] Table 9 XRD patterns

[0092] Table 10. Results of Carbon NMR Spectroscopy

[0093] Example 12: Stability Test

[0094] The compound in this application will be used as a raw material for preparing a suspension injection; therefore, storage is crucial. Impurities may be introduced or generated during storage, affecting the use of the raw material. Therefore, stability studies were conducted on the raw material. Following the ICH guideline "Stability Testing of New Drug Substances and Formulations," influencing factor tests were performed.

[0095] 1. Test conditions: The high humidity test of this product was conducted at 25℃±2℃, RH: 75%±5%, and high temperature (60℃) with the inner and outer packaging removed for 30 days. The light exposure (total illuminance not less than 1.2×106Lux·hr) was also conducted with the inner and outer packaging removed.

[0096] 2. Sampling and testing: High temperature samples were taken at 5, 10 and 30 days; high humidity samples were taken at 5 and 10 days; and light conditions samples were taken at 5 and 11 days.

[0097] 3. Observation results: See the table below.

[0098] Table 11 Stability test results

[0099] Conclusion: As shown in the table, the active pharmaceutical ingredient (API) of this application is relatively stable under the relevant conditions and no obvious impurities are generated. Therefore, after the API is prepared, it can be stored at room temperature.

[0100] Example 13: Experimental study on in vitro cytotoxicity of normal human hepatocytes

[0101] 1. Experimental Materials

[0102] 1.1 Cells: LO2 cells, a human hepatitis cell line

[0103] 1.2 Drug: Compound of Example 11 of this application, HPLC purity 99.54%

[0104] 1.3 Reagents and Instruments: Modified RPMI-1640 culture medium, penicillin-streptomycin solution, 0.25% trypsin-EDTA, fetal bovine serum, MTT, dimethyl sulfoxide, CO-150 carbon monoxide incubator, SW-CJ-2F medical clean bench, CKX-41-32 inverted microscope, CU600 electric thermostatic water bath, RT-2100C enzyme-linked immunosorbent assay (ELISA) analyzer.

[0105] 2 Experimental Methods

[0106] 2.1 Reagent Preparation

[0107] 2.1.1 Preparation of MTT: Weigh 0.25g of MTT using a precision balance and place it in a 50mL volumetric flask. Add an appropriate amount of PBS, incubate in a 50-60℃ water bath, and shake well to dissolve completely. Add PBS to the mark to prepare a 5mg / kg solution. Filter the solution through a 0.22μm microporous membrane for sterilization, aliquot, and store in a refrigerator at 4℃ protected from light.

[0108] 2.1.2 Preparation of cell cryopreservation solution: Mix 20% serum, 10% DMSO and 70% 1640 medium evenly and store at -20℃.

[0109] 2.1.3 In the preparation of the compound in Example 11 of this application, a stock solution of the drug was prepared using DMSO, and then diluted with culture medium to the concentration of the drug to be used. The final concentration of DMSO was controlled to be ≤0.1%.

[0110] 2.2 LO2 cell culture: Normal human LO2 cells were placed in a 25cm² culture medium. 2 Add approximately 4–5 mL of RPMI-1640 culture medium containing 10% FBS to cell culture flasks and incubate at 37°C in a 5% CO2 saturated humidity incubator. Change the culture medium every 2 days and observe cell growth daily. Once cells reach 80% confluence, passage or cryopreserve them. Use cells from passages 5–7 for formal experiments.

[0111] 2.3 Grouping and Dosing Experiments: The experiment was divided into a normal cell control group and a dosing group with different concentrations according to the preliminary experimental results. The concentrations were 6.0, 12.0, 24.0, 48.0, 96.0, 192, 384, 768, 1200, and 1500 μmol / L.

[0112] 2.4 Hepatocyte MTT assay: Logarithmic growth phase LO2 cells were prepared into a cell suspension of 5.0 × 10³ cells / mL and seeded into 96-well plates. A normal control group and groups treated with different concentrations of the compound described in this application (6.0, 12.0, 24.0, 48.0, 96.0, 192, 384, 768, 1200, and 1500 μmol / L) were included. After 24 h of culture, the culture medium was discarded, and the cells were washed 2–3 times with PBS. Different concentrations of the compound described in this application were added, with 8 replicates per concentration. The plates were incubated at 37°C in a 5% CO₂ incubator. After 24, 48, and 72 h of culture, MTT solution was added at each time point, and the plates were incubated in the dark for 4 h. After 4 h, the supernatant was discarded, and 150 LDMSO was added to each well to dissolve the thiazolyl blue crystals. The plates were gently shaken to ensure uniform dissolution. The absorbance of each well was measured at 490 nm using a microplate reader. The absorbance value per well reflects the number of cells, and the two are directly proportional. The experiment was repeated three times. Cell viability was calculated as follows: Cell viability (%) = Absorbance of each group (OD490) × 100 / Absorbance of the control group (OD490)

[0113] 2.5 Statistical Analysis All data are expressed as mean ± standard deviation and were processed using SPSS 17.0 statistical software. t-tests were performed for statistical analysis; paired t-tests were used for self-comparisons, and unpaired t-tests were used for inter-group comparisons. The significance level was P < 0.05.

[0114] 3 Experimental Results

[0115] Table 12. Experimental results of in vitro cytotoxicity of normal human hepatocytes.

[0116] Conclusion: After 72 hours of administration, the OD values ​​of cells in all groups showed an increasing trend, but the growth rate decreased, indicating that the cells were still in the growth stage and the growth rate was somewhat inhibited. Different concentrations of this drug administered to the groups had no inhibitory effect on cells; compared with the normal group, the cell viability was greater than 90%, and within the range of 6.0–1500 μmol / L, it had almost no inhibitory effect on cell growth and was non-toxic to cells.

[0117] Example 14: Pharmacokinetic Study in Rats

[0118] 1. In vivo high performance liquid chromatography analysis method

[0119] The column was packed with octadecylsilane-bonded silica gel (250 mm × 4.6 mm; 5 μm or equivalent column; ghost peak trapping column: MORHCHEM, 4.6 mm × 50 mm); water was used as mobile phase A and acetonitrile as mobile phase B, and gradient elution was performed according to the table below; the flow rate was 1.0 mL per minute, the column temperature was 40 °C; the detection wavelength was 250 nm; and the injection volume was 20 μl.

[0120] Table 13 Chromatographic mobile phase

[0121] 2. Preparation of plasma samples

[0122] Blank plasma sample: Take about 0.5 ml of blood from the canthus of a rat and place it in a pre-prepared centrifuge tube coated with heparin. Centrifuge at 10,000 rpm for 10 min, take out 200 μL of supernatant, add 600 μL of anhydrous ethanol, vortex for 10 min, centrifuge at 10,000 rpm for 10 min, and take out the supernatant.

[0123] Plasma samples containing Example 11: Take 200 μL of blank rat plasma stored in a refrigerator, thaw at room temperature, and add 20 μL of a series of prepared Example 11 solutions (the compound of Example 11 is dissolved in a mixed solvent of sesame oil and benzyl alcohol) to prepare Example 11 plasma solutions of 10, 5, 2, 1, 0.5 and 0.2 μg / ml. Add 600 μL of anhydrous ethanol to each solution to precipitate the protein, vortex for 10 min, centrifuge at 1000 rpm for 10 min, and take out the supernatant for injection.

[0124] 3. Dosing regimen and sample collection

[0125] Healthy rats were used and fasted for 12 hours before the experiment, but given free access to water. The rats were divided into two groups: one group received an intramuscular injection of the solution from Example 11 (a mixture of sesame oil and benzyl alcohol) at a dose of 120 mg / kg in the leg; the other group received an intramuscular injection of cilostazol solution (cilostazol dissolved in a mixture of sesame oil and benzyl alcohol) at a dose of 120 mg / kg in the leg.

[0126] 3. Dosing regimen and sample collection

[0127] Healthy rats were used and fasted for 12 hours before the experiment, with free access to water. The rats were divided into two groups: one group received an intramuscular injection of the solution from Example 11 (a compound from Example 11 dissolved in a mixture of sesame oil and benzyl alcohol) at a dose of 120 mg / kg in the leg; the other group received an intramuscular injection of cilostazol solution (cilostazol dissolved in a mixture of sesame oil and benzyl alcohol) at a dose of 120 mg / kg in the leg. Blood samples of 0.5 mL were collected from the ocular vein of the rats at different time points before and after administration, collected in heparinized centrifuge tubes, centrifuged at 10,000 rpm for 10 min, and 0.2 mL of the supernatant was collected in centrifuge tubes and stored at -4°C. When determining plasma drug concentration, anhydrous ethanol was added to the plasma sample to precipitate the protein, followed by vortexing for 10 min, centrifugation at 10,000 rpm for 10 min, and the supernatant was taken for HPLC analysis. The blood drug concentration-time curve was plotted, and the measured blood drug concentration-time data were processed by a single-compartment model to obtain pharmacokinetic parameters for analysis.

[0128] Table 14 Pharmacokinetic Experiment Results

[0129] AUC of lauroylcilostazol in Example 11 0-720hThe AUC of lauroyl cilostazol was 390.28±19.56 h·μg / mL, which was significantly higher than that of the same dose of cilostazol administered intramuscularly (P<0.05). At the same time, the plasma clearance rate (CL / F) was 0.30±0.01 L / (h·kg), which was significantly lower than that of the cilostazol group (0.61±0.11 L / (h·kg), P<0.05). This indicates that the in vivo clearance rate of lauroyl cilostazol in Example 11 was reduced, the retention time was prolonged, and the AUC was significantly increased, indicating that it had a more obvious sustained-release effect than cilostazol.

Claims

1. Lauroylsilostazol or its solvate as shown in formula (Ⅰ):

2. The lauroylcilostazol according to claim 1, characterized in that, Lauroyl cilostazol is crystalline, and the X-ray powder diffraction pattern of the lauroyl cilostazol crystals has characteristic peaks at diffraction angles 2θ: 5.30±0.2, 7.18±0.2, 9.54±0.2, 13.72±0.2, 14.60±0.2, 16.80±0.2, 16.90±0.2, 18.46±0.2, 19.86±0.2, 20.98±0.2, 21.08±0.2, 22.40±0.2, 23.74±0.2, 25.20±0.2, 26.36±0.2, 26.40±0.2, 27.86±0.2°.

3. The method for preparing lauroylcilostazol according to claim 1, comprising steps 1 and 2: Step 1: Chloromethyl lauryl ester is prepared by reacting dodecyl chloride with paraformaldehyde in the presence of a catalyst; Step 2: Prepare formula (Ⅰ) by reacting the product from Step 1 with cilostazol in the presence of a solvent and a catalyst; The reaction formula is as follows:

4. The method for preparing lauroylsilostazol according to claim 3, wherein the catalyst in step 1 is zinc chloride or aluminum trichloride; the reaction solvent in step 2 is selected from N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, tetrahydrofuran, and dioxane; and the catalyst in step 2 is selected from sodium iodide.

5. The method for preparing lauroylsilostazol according to claim 4, wherein the catalyst in step 1 is zinc chloride.

6. The method for preparing lauroylsilostazol according to claim 4, wherein the reaction solvent in step 2 is N,N-dimethylformamide.

7. The method for preparing lauroylsilostazol according to claim 3, further comprising step 3: preparing pharmaceutical grade raw material of formula (I) from crude product of formula (I) in a crystallization solvent, wherein the crystallization solvent of step 3 is selected from one or more of ethyl acetate, n-hexane, anhydrous ethanol, and anhydrous methanol; and the temperature of the crystallization process is 0-10℃.

8. A pharmaceutical composition comprising lauroylcilostazol of claim 1 and a pharmaceutically acceptable carrier.

9. The use of lauroylsilostazol according to claim 1 in the preparation of a medicament for treating cerebral infarction, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease, and acute coronary syndrome.

10. The use of lauroylcilostazol according to claim 1 for the treatment of cerebral infarction, cerebrovascular disease, atherosclerosis, diabetic complications, peripheral vascular disease, Raynaud's disease, intermittent claudication, ischemic heart disease and acute coronary syndrome.